{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:19:24Z","timestamp":1787818764329,"version":"build-2784847793"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Eslicarbazepine acetate (ESL) is a new anti-epileptic drug (AED) chemically related to oxcarbazepine (OXC) and carbamazepine (CBZ) and is increasingly used in clinical practice. The purpose of the study was to investigate 2-way pharmacokinetic interactions between ESL and other AEDs as compared to OXC and CBZ.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Anonymous data regarding age, gender, use of AEDs, daily doses and serum concentration measurements of ESL, OXC, CBZ and lamotrigine (LTG) and other AEDs were retrieved from 2 therapeutic drug monitoring (TDM) databases in Norway. Drugs were categorized according to their known potential for interactions. Concentration\/dose (C\/D) ratios were calculated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Data from 1100 patients were available. The C\/D ratios of ESL and OXC were unchanged in combination with enzyme-inducing AEDs or valproate (VPA). The C\/D ratio of CBZ decreased by 40% and 22% in combination with other enzyme-inducing AEDs or VPA, respectively, pointing to an increased clearance. ESL demonstrated no significant enzyme-inducing effect on LTG metabolism although there was a 20% and 34% decrease in the C\/D ratio of LTG in combination with OXC and CBZ, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Possible pharmacokinetic interactions have been studied for ESL as compared to OXC and CBZ. The pharmacokinetics of ESL is not affected by enzyme-inducing AEDs or VPA and does not affect the metabolism of LTG in contrast to OXC and CBZ. The study demonstrates the value of using TDM databases to explore the potential for pharmacokinetic interactions of new AEDs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000306","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T15:15:00Z","timestamp":1468509300000},"page":"499-505","source":"Crossref","is-referenced-by-count":22,"title":["The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice"],"prefix":"10.1097","volume":"38","author":[{"given":"Cecilie","family":"Johannessen Landmark","sequence":"first","affiliation":[{"name":"Department of Life Sciences and Health, Faculty of Health Sciences, Oslo and Akershus University College of Applied Sciences;"},{"name":"The National Center for Epilepsy, Sandvika;"},{"name":"Department of Pharmacology, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torleiv","family":"Svendsen","sequence":"additional","affiliation":[{"name":"The National Center for Epilepsy, Sandvika;"},{"name":"Department of Neurology, Innlandet Hospital Trust, Lillehammer;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Dinarevic","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Health, Faculty of Health Sciences, Oslo and Akershus University College of Applied Sciences;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben F.","family":"Kufaas","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Health, Faculty of Health Sciences, Oslo and Akershus University College of Applied Sciences;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Reimers","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, St. Olavs University Hospital;"},{"name":"Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eylert","family":"Brodtkorb","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine; and"},{"name":"Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arton","family":"Baftiu","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Health, Faculty of Health Sciences, Oslo and Akershus University College of Applied Sciences;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margrete L.","family":"Burns","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[{"name":"The National Center for Epilepsy, Sandvika;"},{"name":"Department of Pharmacology, Oslo University Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11596290-000000000-00000","article-title":"Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses","volume":"26","author":"Falc\u00e3o","year":"2012","journal-title":"CNS Drugs"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"e00124","DOI":"10.1002\/prp2.124","article-title":"Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action","volume":"3","author":"Soares-da-Silva","year":"2015","journal-title":"Pharmacol Res Perspect."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.10.005","article-title":"Eslicarbazepine acetate: an update on efficacy and safety in epilepsy","volume":"108","author":"Verrotti","year":"2014","journal-title":"Epilepsy Res."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/epi.12242","article-title":"Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers","volume":"54","author":"Elger","year":"2013","journal-title":"Epilepsia"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":"Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2011.10.003","article-title":"Host factors affecting antiepileptic drug delivery-pharmacokinetic variability","volume":"64","author":"Johannessen Landmark","year":"2012","journal-title":"Adv Drug Deliv Rev."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":"The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response","volume":"19","author":"Bartoli","year":"1997","journal-title":"Ther Drug Monit."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","article-title":"Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy","volume":"57","author":"Gidal","year":"2003","journal-title":"Epilepsy Res"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":"Effect of antiepileptic drug comedication on lamotrigine clearance","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000169418.31275.a7","article-title":"Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service","volume":"25","author":"Reimers","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/j.1528-1167.2011.03217.x","article-title":"The effect of age and comedication on lamotrigine clearance, tolerability and efficacy","volume":"52","author":"Arif","year":"2011","journal-title":"Epilepsia"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eplepsyres.2011.02.002","article-title":"Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol","volume":"94","author":"Reimers","year":"2011","journal-title":"Epilepsy Res."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","article-title":"Gender differences in pharmacological response","volume":"83","author":"Anderson","year":"2008","journal-title":"Int Rev Neurobiol."},{"issue":"pt B","key":"R18-20230814","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.nbd.2014.05.011","article-title":"Gender issues in antiepileptic drug treatment","volume":"72","author":"Perucca","year":"2014","journal-title":"Neurobiol Dis."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00228-007-0308-2","article-title":"Lamotrigine in children and adolescents: the impact on its serum concentrations and on the extent of drug interactions","volume":"63","author":"Reimers","year":"2007","journal-title":"Eur J Clin Pharmacol."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1177\/0091270004266617","article-title":"Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy","volume":"44","author":"Rey","year":"2004","journal-title":"J Clin Pharmacol."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1097\/01.ftd.0000155342.93489.fd","article-title":"10-hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs","volume":"27","author":"Armijo","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.55.4.588","article-title":"Adding valproate to lamotrigine: a study of their pharmacokinetic interaction","volume":"55","author":"Kanner","year":"2000","journal-title":"Neurology"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second and third generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Exp Rev Neurother."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab Dispos."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(92)90098-E","article-title":"Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients","volume":"11","author":"McKee","year":"1992","journal-title":"Epilepsy Res."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00007691-199506000-00002","article-title":"Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase?","volume":"17","author":"Svinarov","year":"1995","journal-title":"Ther Drug Monit."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2125.1997.00607.x","article-title":"The mechanism of the carbamazepine-valproate interaction in humans","volume":"44","author":"Bernus","year":"1997","journal-title":"Br J Clin Pharmacol."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/sj.npp.1300831","article-title":"Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine","volume":"30","author":"Theis","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","article-title":"The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy","volume":"95","author":"Gulcebi","year":"2011","journal-title":"Epilepsy Res."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e3181ceecc6","article-title":"UGT2B7_-161C>T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study","volume":"32","author":"Blanca S\u00e1nchez","year":"2010","journal-title":"Ther Drug Monit."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13318-014-0247-0","article-title":"Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine","volume":"41","author":"Reimers","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0000000000000272","article-title":"Therapeutic drug monitoring of clobazam and its metabolite\u2014impact of age and comedication on pharmacokinetic variability","volume":"38","author":"Burns","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eplepsyres.2013.02.020","article-title":"Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol\/levonorgestrel oral contraceptive in healthy women","volume":"105","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res."},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/17425255.3.2.149","article-title":"Stereoselectivity in drug metabolism","volume":"3","author":"Lu","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1515\/DMDI.2007.22.2-3.79","article-title":"Chirality and pharmacokinetics: an area of neglected dimensionality?","volume":"22","author":"Hutt","year":"2007","journal-title":"Drug Metabol Drug Interact."},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","article-title":"Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine","volume":"44","author":"Hainzl","year":"2001","journal-title":"Epilepsy Res."},{"key":"R38-20230814","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pds.2269","article-title":"Drug safety aspects of antiepileptic drugs- focus on pharmacovigilance","volume":"21","author":"Johannessen Landmark","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1586\/ecp.12.10","article-title":"Methodologies used to identify and characterize interactions among antiepileptic drugs","volume":"5","author":"Johannessen Landmark","year":"2012","journal-title":"Exp Rev Clin Pharmacol."},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1111\/epi.12801","article-title":"Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study","volume":"55","author":"Samsonsen","year":"2014","journal-title":"Epilepsia."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201608000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:03:49Z","timestamp":1692050629000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201608000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000306","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}